Flow Medical

Executive Summary

Flow Medical is a San Francisco-based medical device company developing an integrated, real-time feedback system for catheter-directed thrombolysis (CDT) in pulmonary embolism (PE) treatment. Their steerable, all-in-one catheter aims to streamline procedures, improve lytic delivery, and provide physicians with data to monitor clot resolution, potentially personalizing treatment and reducing complications. Founded in 2019, Flow Medical operates in the cardiovascular and medical devices space, targeting a significant unmet need in PE management. While the company is still in early stages with no disclosed funding or clinical milestones, its innovative approach to CDT—combining delivery and monitoring in a single device—positions it to address procedural inefficiencies and variability in outcomes. The platform's real-time feedback could enhance physician decision-making and patient safety, setting it apart from conventional CDT systems. However, as a pre-commercial entity, Flow Medical faces typical risks including regulatory hurdles, clinical validation, and capital requirements. Its success will depend on securing funding, initiating clinical trials, and demonstrating safety and efficacy to gain FDA clearance.

Upcoming Catalysts (preview)

• Q1 2027Series A Funding Announcement40% success
• Q3 2027First-In-Human Clinical Trial Initiation35% success
• Q2 2028FDA 510(k) Submission for Catheter System20% success